Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright lowered the firm’s price target on Lexeo Therapeutics to $13 from $15 and kept a Buy rating on the shares. The price cut was made as the firm pointed out the share dilution from the most recent equity raise.
Earlier on October 17, Leerink analyst Mani Foroohar also lowered the firm’s price target on Lexeo Therapeutics to $18 from $20 with an Outperform rating on the shares. Leerink noted the company’s announcement of a secondary offering and a concurrent private placement, which together are expected to generate gross proceeds of $135 million.
The financing was announced alongside additional data for the company’s compound, LX2020 PKP2. Leerink commented that strengthening the balance sheet before starting the pivotal trial for FACM and releasing further PKP2 data is a logical step. The firm believes that this action shifts the focus to Lexeo’s data, rather than concerns about the company’s financial overhang.
Lexeo Therapeutics Inc. (NASDAQ:LXEO) is a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases with high unmet need in the US.
While we acknowledge the potential of LXEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
